NCT03752216已完成4 期
Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients with Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study
ARCAGY/ GINECO GROUP30 个研究点 分布在 1 个国家目标入组 141 人开始时间: 2019年4月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 141
- 试验地点
- 30
- 主要终点
- Toxicities inducing dose modifications of Niraparib between the start to the cycle 3 (interruption, discontinuation and dose reduction).
研究概览
简要总结
This is a longitudinal, national, open, multi-centre phase IV study which will recruit up to 141 patients with ovarian cancer in late relapse treated with niraparib according to the labelling In France.
详细描述
The aim of NiQoLe, phase IV study is to evaluate tolerability of Niraparib and the management by the physicians of the side-effects in real life in France. The study will also generate complementary data of NOVA trial on longitudinal follow up of closed symptoms and side effects reported by the patients especially with the NCI PRO (Patient-Reported Outcome)-CTCAE system. Specific oncogeriatric data will be collected among on a subgroup of elderly patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Open
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •I-1 Female patients must be ≥ 18 years of age. I-2 Signed informed consent and ability to comply with treatment and follow-up. I-3 Patients with histologically proved high grade epithelial ovarian cancer or fallopian tube or primary peritoneal adenocarcioma.
- •I-4 Platine sensitive and ovarian, fallopian or peritoneal cancer recurrent patients with a complete response or partial response after a line of platine based chemotherapy.
- •I-5 Participant must have adequate organ function, defined as follows:
- •Absolute neutrophil count ≥ 1,500/μL
- •Platelets ≥ 100,000/μL
- •Hemoglobin ≥ 9 g/dL
- •Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation
- •Total bilirubin ≤ 1.5 x ULN (≤2.0 in patients with known Gilberts syndrome) OR direct bilirubin ≤ 1 x ULN
- •Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN I-6 Patients with an indication of maintenance by Niraparib after platine based chemotherapy according to the labelling (see appendix 17).
- •I-7 As this study will include patients in France, a subject will be eligible in this study only if either affiliated to, or a beneficiary of, a social category.
- •I-8 Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤
- •I-9 Participant receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy.
- •I-10 Participant must agree to not donate blood during the study or for 90 days after the last dose of Niraparib.
- •I-11 Female participant has a negative urine or serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 1 month after the last dose of study treatment, or is of nonchildbearing potential.
- •I-12 Participant must agree to not breastfeed during the study or for 1 month after the last dose of Niraparib.
- •I-13 Participant must have normal blood pressure or adequately treated and controlled hypertension
排除标准
- •E-1 Known hypersensitivity or allergy to active principle or to any components or excipients of the Niraparib formulation.
- •E-2 Participant must not be simultaneously enrolled in any interventional clinical trial.
- •E-3 Participant must not have had major surgery ≤ 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects.
- •E-4 Participant must not have received investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.
- •E-5 Participant last treatment with platinum-based chemotherapy was ≥12 weeks from initiation of protocol therapy E-6 Participant has had radiation therapy encompassing >20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy.
- •E-7 Participant must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks NiQoLe - Study protocol - v3.0 on 08/10/2020 Page 10 on 109 N° EudraCT: 2018-002274-44 prior to initiating protocol therapy. E-8 Participant must not have received colony stimulating factors (e.g., granulocyte colonystimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy. E-9 Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment. E-10 Participant must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). E-11 Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent. E-12 Participant must not be deprived of liberty, under guardianship or under trusteeship.
研究组 & 干预措施
NIRAPARIB
Experimental
Oral Niraparib Daily
干预措施: Niraparib (Drug)
结局指标
主要结局
Toxicities inducing dose modifications of Niraparib between the start to the cycle 3 (interruption, discontinuation and dose reduction).
时间窗: 3 months
Evaluate treatment toxicities
次要结局
- Duration of Niraparib treatment(Up to 18 months.)
- Self-reported symptoms and side effects with the NCI PRO-CTCAE(Up to 18 months.)
- Reasons of the dose modification of Niraparib(Up to 18 months.)
- Pain related to the treatment by Visual Analogic Scale (VAS)(Up to 18 months.)
- Self-reported fatigue by patient by FACT-F questionnaire (Functional Assessment of Cancer Therapy General - Fatigue)(Up to 18 months.)
- Side effects of interest (HTA, anemia, thrombocytopenia)(Up to 18 months.)
- Initial cognitive functions by FACT-cog (Functional Assessment of Cancer Therapy - Cognitive Function) questionnaire(At the inclusion visit)
- Plasma level of Niraparib before Niraparib administration(3 months)
- Geriatric Depression Scale (score range from 0 [better outcome] to 30 [worse outcome])(Up to 6 months.)
- General health-related quality of life by FACT-G questionnaire (Functional Assessment of Cancer Therapy General)(Up to 18 months.)
- Time to first subsequent line of anti-cancer therapy(Up to 18 months.)
- Overall response rate(Up to 18 months.)
研究者
研究点 (30)
Loading locations...
相似试验
已完成
不适用
Effects of Olfactory Training on the Brain Function in T2DM Patients With Mild Cognitive ImpairmentType 2 Diabetes MellitusMild Cognitive ImpairmentNCT06327633The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School60
进行中（未招募）
不适用
An open, phase IV, multicentre, study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children aged 11-12 years, previously vaccinated with GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) or GSK Biologicals’ DTPa-IPV/Hib and HBV (Engerix™- B) vaccines at the ages of 3, 5 and 11 months in clinical trial DTPa-HBV-IPV-031 (217744/031). - DTPa-HBV-IPV-126 BST:031Antibody persistence and hepatitis B vaccine challenge at 11-12 years of age (excluding 13th birthday), after primary vaccination with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) or GSK Biologicals’ HBV vaccine (Engerix-B) given at the ages of 3, 5 and 11 months.EUCTR2009-016911-39-SKGlaxoSmithKline Biologicals
尚未招募
4 期
A National Multicenter, Real-world Study of Linperlisib in the Treatment of LymphomaIndolent B-cell LymphomaNCT06343935Shanghai YingLi Pharmaceutical Co. Ltd.88
已完成
不适用
Observational Study on the Use of Akynzeo® in Patients Receiving HECChemotherapy-Induced Nausea and VomitingNCT03649230Purdue Pharma, Canada207
已完成
4 期
Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal WomenVasomotor SymptomsNCT00472004Wyeth is now a wholly owned subsidiary of Pfizer204